Integrin alphaIIb-subunit cytoplasmic domain mutations demonstrate a requirement for tyrosine phosphorylation of beta3-subunits in actin cytoskeletal organization.
Using truncated or mutated alphaIIb integrin cytoplasmic domains fused to the alphaV extracellular domain and expressed with the beta3 integrin subunit, we demonstrate that the double mutation of proline residues 998 and 999 to alanine (PP998/999AA), previously shown to disturb the C-terminal conformation of the alphaIIb integrin cytoplasmic domain, prevents tyrosine phosphorylation of beta3 integrin induced by Arg-Gly-Asp peptide ligation. This mutation also inhibits integrin mediated actin assembly and cell adhesion to vitronectin. In contrast, progressive truncation of the alphaIIb-subunit cytoplasmic domain did not reproduce these effects. Interestingly, the PP998/999AA mutations of alphaIIb did not affect beta3 tyrosine phosphorylation, cell adhesion, or actin polymerization induced by manganese. Exogenous addition of manganese was sufficient to rescue beta3 phosphorylation, cell adhesion, and actin assembly in cells expressing the PP998/999AA mutation when presented with a vitronectin substrate. Further, induction of the high affinity conformation of this mutant beta3 integrin by incubation with either Arg-Gly-Asp peptide or exogenous manganese was equivalent. These results suggest that the extracellular structure of beta3 integrins in the high affinity conformation is not directly related to the structure of the cytoplasmic face of the integrin. Moreover, the requirement for beta3 phosphorylation is demonstrated without mutation of the beta3 subunit. In support of our previous hypothesis of a role for beta3 phosphorylation in adhesion, these studies demonstrate a strong correlation between beta3 tyrosine phosphorylation and assembly of a cytoskeleton competent to support firm cell adhesion.
Yamodo
Innocent H
IH
Department of Cell and Developmental Biology, SUNY Upstate Medical University, Syracuse, New York 13210, USA.
Blystone
Scott D
SD
D000199:Actins / Q000378:metabolism*; D000595:Amino Acid Sequence; D001665:Binding Sites; D002448:Cell Adhesion; D015815:Cell Adhesion Molecules / Q000502:physiology; D045744:Cell Line, Tumor; D003598:Cytoskeletal Proteins / Q000502:physiology; D003599:Cytoskeleton / Q000378:metabolism*; D015870:Gene Expression; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000235:genetics / Q000502:physiology*; D020014:K562 Cells; D008345:Manganese / Q000494:pharmacology; D008969:Molecular Sequence Data; D050506:Mutant Chimeric Proteins / Q000235:genetics / Q000378:metabolism; D009154:Mutation; D009842:Oligopeptides / Q000494:pharmacology; D010766:Phosphorylation; D040201:Platelet Membrane Glycoprotein IIb / Q000235:genetics* / Q000502:physiology*; D011487:Protein Conformation; D021122:Protein Subunits / Q000235:genetics / Q000502:physiology; D013329:Structure-Activity Relationship; D014443:Tyrosine / Q000378:metabolism*
D000199:Actins; D015815:Cell Adhesion Molecules; D003598:Cytoskeletal Proteins; D039302:Integrin alphaVbeta3; D050506:Mutant Chimeric Proteins; D009842:Oligopeptides; D040201:Platelet Membrane Glycoprotein IIb; D021122:Protein Subunits; D014443:Tyrosine; D008345:Manganese; C047981:arginyl-glycyl-aspartic acid